Stoke Therapeutics develops antisense oligonucleotide medicines using its proprietary TANGO technology to increase gene expression by targeting non-productive RNA splicing. The platform has identified thousands of genes potentially addressable to treat monogenic diseases caused by loss or reduction of gene function. Stoke is rapidly advancing its lead program for Dravet Syndrome and expects to enter the clinic by early 2020. It has also built a pipeline of candidates targeting central nervous system disorders as well as diseases of the eye, ear, liver, and kidney. Financially, the company launched in 2018 with a $40 million Series A from Apple Tree Partners and recently completed a $90 million Series B to fund clinical advancement. The Series B brings crossover and institutional support intended to accelerate progress toward the clinic. Stoke Therapeutics is focused on increasing gene expression by using antisense oligonucleotides to modulate RNA splicing. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform has validated hundreds of disease target genes that could be up-regulated. The company is prioritizing therapeutic programs directed at antisense-addressable tissues, including the central nervous system, eye, and liver. Its initial focus is inherited diseases caused by reduced function of a single mutated gene, with potential applicability to augmenting non-mutated genes to prevent or reverse disease. Stoke’s scientific founder is Adrian Krainer, and the leadership team includes experienced industry executives such as CEO Edward M. Kaye. Stoke was launched in 2018 and completed a $40 million Series A to advance multiple preclinical programs.

Total raised

$130M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2018